| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | -0.37 | 0.2 |
| mRNA | lapatinib | FIMM | pan-cancer | AAC | -0.21 | 0.2 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.2 | 0.2 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.2 | 0.1 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.17 | 0.04 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.17 | 0.3 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.15 | 0.4 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.14 | 0.2 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.2 |
| mRNA | Axitinib | FIMM | pan-cancer | AAC | -0.14 | 0.4 |